Treatment News : Lasting CD4 Increases With IL-2

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2007

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 12, 2007

Lasting CD4 Increases With IL-2

Results from a new study justify scientists’ continuing interest in interleukin-2 (IL-2) therapy for HIV. The French study, published in the September issue of AIDS, found that CD4 cell increases from the immune-based therapy were robust and long lasting, regardless of the potency of antiviral combination with which it was paired.

Yves Levy, MD, PhD, and his colleagues conducted a long-term follow-up of two earlier IL-2 studies in France—one, ANRS048, which paired IL-2 with the two nucleoside analogues, Retrovir (zidovudine) and Videx (didanosine), and a second study, ANRS079, which paired IL-2 with triple combination therapy including a protease inhibitor. A total of 131 people from both studies were ultimately treated with an average of 10 cycles of IL-2—each cycle involved a series of injections spaced eight weeks apart—and have been followed for at least three and a quarter years.

The results were quite promising. After 170 weeks on treatment, patients’ CD4s averaged 791 cells—an approximate 428-cell increase since entering the trials. One surprising finding was that, regardless of the antiviral regimen they initiated at the start of the studies, participants experienced sharp and sustained increases in their CD4s. Those who initiated the study with an antiviral regimen containing a protease inhibitor did maintain better control of virus, however, than those who initiated with just two nucleoside analogues.

Although IL-2 is available in the United States, it is not currently approved for use in HIV disease. A large international study is currently ongoing and will help determine whether the CD4 increases associated with IL-2 therapy actually result in improved health and survival for people with HIV.


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    july8th69
    brooklyn
    New York


    ernienyc
    Bronx
    New York

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.